An epidemiological study of the susceptibility and frequency of multiple-drug-resistant strains of Pseudomonas aeruginosa isolated at medical institutes nationwide in Japan

Journal of Infection and Chemotherapy

Volumn 11, Issue 2, 2005, Pages 64-70

  Tsuji, Akiyoshi ^a,b   Kobayashi, Intetsu ^b   Oguri, Toyoko ^b   Inoue, Matsuhisa ^b   Yabuuchi, Eiko ^b   Goto, Sachiko ^b  

^a TOHO UNIVERSITY   (Japan)

^b Pseudomonas aeruginosa Epidemiol R   (Japan)

Author keywords

Epidemiology; Multi drug resistant; Pseudomonas aeruginosa; Susceptibility

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; BIAPENEM; CEFEPIME; CEFOPERAZONE; CEFOSELIS; CEFOZOPRAN; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PANIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOOD; CEREBROSPINAL FLUID; JAPAN; MINIMUM INHIBITORY CONCENTRATION; MUCUS; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PUS; SPUTUM; URINE;

EID: 18444397165     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-005-0377-z     Document Type: Article

References (21)

1. Boukadida J, De Montalembert M, Lenoir G, Scheinmann P, Veron M, Berche P. Molecular epidemiology of chronic pulmonary colonisation by Pseudomonas aeruginosa in cystic fibrosis. J Med Microbiol 1993;38:29-33.
2. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-88.
3. Nordmann P, Guibert M. Extended-spectrum β-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother 1998;42:128-31.
4. Kobayashi I, Hasegawa M, Nishida M. Alteration of serotype and drug susceptibility of some Pseudomonas aeruginosa isolates by exposure to human serum and polymorphonuclear leukocytes. Kansenshogaku Zasshi 1994;68:500-7.
5. Kobayashi H. Airway biofilm disease. Int J Antimicrob Agents 2001;17:351-6.
6. Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 2000;38:1818-22.
7. Maeda K, Sawaki M, Mikasa K, Konishi M, Teramoto S, Mori K, et al. A clinical study of respiratory infections due to mucoid Pseudomonas aeruginosa diagnosed by transtracheal aspiration. Kansenshogaku Zasshi 1994;68:1472-8.
8. Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999;43:2877-80.
9. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45:105-16.
10. Senda K, Arakawa Y, Nakashima K, Ito H, Ichiyama S, Shimokata K, et al. Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother 1996;40:349-53.
11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, fifth ed. M7-A5: 2000. Wayre, PA: NCCL 5; 2000.
12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; eleventh informational supplement. M100-S11, 2001. Wayre, PA: NCCLS: 2001.
13. Takigawa K, Fujita J, Negayama K, Yamagishi Y, Yamaji Y, Ouchi K, et al. Nosocomial outbreak of Pseudomonas cepacia respiratory infection in immunocompromised patients associated with contaminated nebulizer devices. Kansenshogaku Zasshi 1993;67:1115-25.
14. Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H, et al. Convenient test for screening metallo-β-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol 2000;38:40-3.
15. Li XZ, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 1994;38:1732-41.
16. Kobayashi I, Hasegawa M, Miyazaki S, Nishida M, Goto S. In vitro and in vivo changes of serotype in Pseudomonas aeruginosa isolates by anti-pseudomonal drugs. J Antibiot (Tokyo) 1994;47:72-9.
17. Kouda M, Fukuhara J, Takeuchi M, Ohgawara M, Matsuzaki H, Tohi H, et al. Estimation of antibacterial activity of various antibiotics against Pseudomonas aeruginosa by score method. Jpn J Antibiot 1999;52:458-68.
18. Nakae M, Sugahara Y, Sasaki H, Yasui H, Imai C, Hasegawa Y, et al. Serotypes and drug susceptibility of Pseudomonas aeruginosa isolated from clinical specimens. Jpn J Antibiot 1997;50:187-94.
19. Hikida M, Terashima S, Sato Y, Okamoato R, Inoue M. Comparative antibacterial activity of carbapenems against P. aeruginosa (1). Jpn J Antibiot 2001;54:571-9.
20. Niitsuma K, Saitoh M, Kojimabara M, Kashiwabara N, Aoki T, Tomizawa M, et al. Antimicrobial susceptibility of Pseudomonas aeruginosa isolated in Fukushima Prefecture. Jpn J Antibiot 2001;54:79-87.
21. Sasaki M, Hiyama E, Takesue Y, Kodaira M, Sueda T, Yokoyama T. Clinical surveillance of surgical imipenem-resistant Pseudomonas aeruginosa infection in a Japanese hospital. J Hosp Infect 2004;56:111-18.